Monkeypox Info & Updates

Información acerca de la viruela del mono… [Spanish]

MPX Info & Updates

MPX (previously known as monkeypox) is circulating in our community, and we want to make sure you have the info you need about what’s going on.

Symptoms often start with flu-like symptoms, including fever, headache, and fatigue, but not everyone has these symptoms. 1 to 3 days later, people may get a rash or “blisters” on the face, arms, legs, hands, feet, and genital and anal areas – the genital/anal rash appear to be very common during this outbreak. It usually takes around 5 to 14 days after any exposure for symptoms to appear (the “incubation period”). Find more answers to Frequently Asked Questions.

Diagnosis & Treatment

Magnet is available for diagnosis and treatment for people that develop rashes around their genitals and/or anal area, and/or on face, hands/feet, and other parts of the body that may be caused by MPX or another infection. Call us at 628-212-8038 to schedule a visit.


Testing for MPX involves taking a swab of the rash to see if it might be caused by MPX or a different infection. Only those experiencing rash or blister-like symptoms may receive testing at this time, which involves taking a swab of the rash. Call us at 628-212-8038 to schedule a visit.


MPX vaccinations are now available to:

  • Cis gay, bisexual, and other men who have sex with men
  • All transgender and nonbinary individuals (who have sex with cis men or trans folks assigned male at birth)
  • People in the sex trade of any sexual orientation or gender identity
  • People who have had close contact in the last 6 months with someone with suspected or confirmed MPX
  • People who had close contact with others at a venue or event in a social group in the past 6 months where a suspected or confirmed MPX case was identified
  • People who anticipate experiencing any of the above
  • People who are living with HIV
  • People who are taking or are eligible to take PrEP
  • Lab workers who routinely perform MPX virus testing 
  • Clinicians who are likely to collect lab samples from people with MPX
  • Clinicians who have had a high-risk occupational exposure (e.g., examined MPX lesions or collected MPX specimens without using recommend personal protective equipment)

We are providing the JYNNEOS vaccine. The JYNNEOS vaccine is a two-dose vaccine and we recommend  that you receive both doses at least 28 days apart for maximal protection. Although vaccine supply is still somewhat limited, most people who need access to the JYNNEOS vaccine should be able to receive dose #1 and/or dose #2. Please sign up online to join our MPX Vaccine Waitlist.

Please note: If you have previously signed up on our waitlist to receive a vaccine, we have recently transitioned to a new waitlist management system. Please re-confirm your need for vaccination and place on our waitlist by responding to the message we sent to you.

If you have added your name to the waitlist, we will call or email to schedule an appointment when a vaccine becomes available. Vaccines come to us from the federal government, and we are filling appointments from the waitlist as quickly as we can. Please note that we are not a mass vaccination site—we may not be your quickest option. 

The mass vaccination site for San Francisco is Zuckerberg San Francisco General Hospital, located at 1001 Potrero, Building 30. If you are on our vaccine waitlist and have not received a call from us about scheduling a vaccine appointment, we encourage you to drop in to ZSFG if you are able to.  

Second doses of vaccine

We are providing the second dose of the JYNNEOS vaccine to people who are beyond 28 days from receiving their first dose. 

Intradermal dosing

In order to maximize the availability of the JYNNEOS vaccine to community members, the FDA has provided authorization for an intradermal vaccination that we are now required to follow. Instead of administering the JYNNEOS vaccine as a subcutaneous injection, the JYNNEOS vaccine is now administered as an intradermal injection. This alternative way to administer the vaccine allows as many as five times the number of doses to come from a single vial of JYNNEOS . The intradermal administration works as well as the subcutaneous administration despite the lower dose. People under age 18 and people with a history of keloid scarring will continue to receive a subcutaneous dose. For more information, see our FAQs about intradermal dosing.

Last updated on October 4, 2022. SFAF will continue to update this page as additional information becomes available.

We need your support! Sign the petition to increase access to treatment and prevention for MPX.

SFAF MPX Town Hall

San Francisco AIDS Foundation hosted a community town hall on MPX to share what we know about this infection including how it's transmitted, how to prevent it, the number of infections in the Bay Area, and how to access vaccines for MPX. We also include information on how to get involved in vaccine advocacy as San Francisco faces vaccine shortages.